IMNM Projected Dividend Yield
Immunome Inc ( NASDAQ : IMNM )Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. Co.'s portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. 20 YEAR PERFORMANCE RESULTS |
IMNM Dividend History Detail IMNM Dividend News IMNM Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |